YAP is also overexpressed in cholangiocarcinoma, cancer of the biliary duct, with increased expression corresponding with a worse patient outcome [154], in some rare instances due to loss of NF2 function [155,156], while YAP promotes therapeutic resistance in in vitro models of hepatocellular carcinoma [157]. The gene discussed is YAP1; the disease is cholangiocarcinoma.